The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Promising novel treatment approaches in WM: non-covalent BTKis and immunotherapies
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses promising novel treatment approaches for patients with Waldenström’s macroglobulinemia (WM), including combination approaches with Bruton’s tyrosine kinase (BTK) inhibitors, and non-covalent BTK inhibitors, such as pirtobrutinib and nemtabrutinib. Dr Castillo also highlights the promise of several immunotherapies, including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR-T cell therapy. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting fees or research funds from Abbvie, AstraZeneca, BeiGene, Casma, Cellectar, Janssen, Pharmcyclics, Roche, TG Therapeutics.
